DE Burlo Group Inc. Sells 500 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

DE Burlo Group Inc. reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 9.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,617 shares of the company’s stock after selling 500 shares during the quarter. DE Burlo Group Inc.’s holdings in Neurocrine Biosciences were worth $630,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Caprock Group LLC bought a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at $236,000. Charles Schwab Investment Management Inc. raised its position in shares of Neurocrine Biosciences by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company’s stock valued at $104,089,000 after buying an additional 15,266 shares in the last quarter. Tri Ri Asset Management Corp bought a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $3,236,000. Oakworth Capital Inc. acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter worth approximately $379,000. Finally, Avantax Advisory Services Inc. increased its stake in Neurocrine Biosciences by 11.4% in the fourth quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company’s stock valued at $395,000 after acquiring an additional 297 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NBIX shares. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 20th. Evercore ISI decreased their target price on Neurocrine Biosciences from $190.00 to $185.00 and set an “outperform” rating on the stock in a research report on Thursday. HC Wainwright dropped their target price on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a “buy” rating for the company in a report on Tuesday. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $150.00 price objective (down from $185.00) on shares of Neurocrine Biosciences in a research report on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $161.14.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $106.73 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $157.98. The stock has a 50 day simple moving average of $107.16 and a two-hundred day simple moving average of $122.08. The company has a market cap of $10.56 billion, a P/E ratio of 32.44, a PEG ratio of 0.77 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. On average, research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Neurocrine Biosciences declared that its Board of Directors has authorized a stock buyback plan on Friday, February 21st that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Insider Activity

In other news, CEO Kyle Gano sold 1,541 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $152.87, for a total transaction of $235,572.67. Following the completion of the sale, the chief executive officer now owns 136,778 shares in the company, valued at $20,909,252.86. The trade was a 1.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Ingrid Delaet sold 623 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $149.29, for a total value of $93,007.67. Following the completion of the transaction, the insider now owns 3,442 shares in the company, valued at approximately $513,856.18. This represents a 15.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 167,906 shares of company stock worth $24,671,530. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.